Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers
Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also fr...
Gespeichert in:
| Veröffentlicht in: | Pharmacogenomics 2016-05, Vol.17 (7), p.795-804 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 804 |
|---|---|
| container_issue | 7 |
| container_start_page | 795 |
| container_title | Pharmacogenomics |
| container_volume | 17 |
| creator | Tká, Ivan Gotthardová, Ivana |
| description | Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies.
rs7903146 C>T and
rs7202877 T>G minor allele carriers were both associated with a smaller reduction in HbA1c after gliptin treatment when compared with major allele carriers. After replication in further studies, these observations could be of clinical significance in helping to identify patients with potentially lower or higher response to gliptin treatment. |
| doi_str_mv | 10.2217/pgs-2016-0011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1793903572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1793903572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-6cabeb2290187c9a6609b936f6857936b4ac8f2b33c70fa8fa2015a72159b5363</originalsourceid><addsrcrecordid>eNp1kE1PHSEUhkmjqR_tsltD4qabqXCYgWHZGKsmJnVx3UoYPHgxd5gpMGnuv5fbq1006eoAed43h4eQL5x9A-DqYn7ODTAuG8Y4_0COuWrbpmctHNRzK6GBlssjcpLzC2PAZcs-kiNQXEqtumPyeL-2abRuesaIJThq84yuZDp5WtZIS0JbRoxl97DazkiBPgU7YMFMf4ey_kOF6FJNR4re1zTFuLbRYcqfyKG3m4yf3-Ypefhxtbq8ae5-Xt9efr9rnFC8NNLVxgFAM94rp62UTA9aSC_7TtU5tNb1HgYhnGLe9t7WL3dWAe_00AkpTsnXfe-cpl8L5mLGkB1uNjbitGTDa4tmolNQ0fN_0JdpSbFuZ0CA1AIAVKWaPeXSlHNCb-YURpu2hjOzE2-qeLMTb3biK3_21roMIz79pd9NV0DvAb-UJWF2Aashs7_VRHAh4n_KXwE_KpD3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326932227</pqid></control><display><type>article</type><title>Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers</title><source>MEDLINE</source><source>PubMed Central</source><creator>Tká, Ivan ; Gotthardová, Ivana</creator><creatorcontrib>Tká, Ivan ; Gotthardová, Ivana</creatorcontrib><description>Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies.
rs7903146 C>T and
rs7202877 T>G minor allele carriers were both associated with a smaller reduction in HbA1c after gliptin treatment when compared with major allele carriers. After replication in further studies, these observations could be of clinical significance in helping to identify patients with potentially lower or higher response to gliptin treatment.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2016-0011</identifier><identifier>PMID: 27166975</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Alleles ; Chymotrypsin - genetics ; Chymotrypsin - metabolism ; Defects ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - genetics ; Diabetes Mellitus, Type 2 - metabolism ; Dipeptidyl-peptidase IV ; Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Enhancers ; Gene expression ; Genotype & phenotype ; gliptins ; GLP-1 receptor agonists ; Glucagon-Like Peptide-1 Receptor - agonists ; Glucose ; Humans ; Hypoglycemic Agents - pharmacokinetics ; Hypoglycemic Agents - therapeutic use ; incretin effect ; Incretins - agonists ; Insulin resistance ; KCNQ1 Potassium Channel - genetics ; KCNQ1 Potassium Channel - metabolism ; Metabolism ; Peptidase ; Pharmacogenomic Testing ; Pharmacogenomic Variants ; Polymorphism, Single Nucleotide ; Potassium ; Proteins ; Studies ; Transcription Factor 7-Like 2 Protein - genetics ; Transcription Factor 7-Like 2 Protein - metabolism ; Type 2 diabetes mellitus</subject><ispartof>Pharmacogenomics, 2016-05, Vol.17 (7), p.795-804</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd May 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-6cabeb2290187c9a6609b936f6857936b4ac8f2b33c70fa8fa2015a72159b5363</citedby><cites>FETCH-LOGICAL-c371t-6cabeb2290187c9a6609b936f6857936b4ac8f2b33c70fa8fa2015a72159b5363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27166975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tká, Ivan</creatorcontrib><creatorcontrib>Gotthardová, Ivana</creatorcontrib><title>Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies.
rs7903146 C>T and
rs7202877 T>G minor allele carriers were both associated with a smaller reduction in HbA1c after gliptin treatment when compared with major allele carriers. After replication in further studies, these observations could be of clinical significance in helping to identify patients with potentially lower or higher response to gliptin treatment.</description><subject>Alleles</subject><subject>Chymotrypsin - genetics</subject><subject>Chymotrypsin - metabolism</subject><subject>Defects</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Dipeptidyl-peptidase IV</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Enhancers</subject><subject>Gene expression</subject><subject>Genotype & phenotype</subject><subject>gliptins</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Glucose</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>incretin effect</subject><subject>Incretins - agonists</subject><subject>Insulin resistance</subject><subject>KCNQ1 Potassium Channel - genetics</subject><subject>KCNQ1 Potassium Channel - metabolism</subject><subject>Metabolism</subject><subject>Peptidase</subject><subject>Pharmacogenomic Testing</subject><subject>Pharmacogenomic Variants</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Potassium</subject><subject>Proteins</subject><subject>Studies</subject><subject>Transcription Factor 7-Like 2 Protein - genetics</subject><subject>Transcription Factor 7-Like 2 Protein - metabolism</subject><subject>Type 2 diabetes mellitus</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1PHSEUhkmjqR_tsltD4qabqXCYgWHZGKsmJnVx3UoYPHgxd5gpMGnuv5fbq1006eoAed43h4eQL5x9A-DqYn7ODTAuG8Y4_0COuWrbpmctHNRzK6GBlssjcpLzC2PAZcs-kiNQXEqtumPyeL-2abRuesaIJThq84yuZDp5WtZIS0JbRoxl97DazkiBPgU7YMFMf4ey_kOF6FJNR4re1zTFuLbRYcqfyKG3m4yf3-Ypefhxtbq8ae5-Xt9efr9rnFC8NNLVxgFAM94rp62UTA9aSC_7TtU5tNb1HgYhnGLe9t7WL3dWAe_00AkpTsnXfe-cpl8L5mLGkB1uNjbitGTDa4tmolNQ0fN_0JdpSbFuZ0CA1AIAVKWaPeXSlHNCb-YURpu2hjOzE2-qeLMTb3biK3_21roMIz79pd9NV0DvAb-UJWF2Aashs7_VRHAh4n_KXwE_KpD3</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Tká, Ivan</creator><creator>Gotthardová, Ivana</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160501</creationdate><title>Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers</title><author>Tká, Ivan ; Gotthardová, Ivana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-6cabeb2290187c9a6609b936f6857936b4ac8f2b33c70fa8fa2015a72159b5363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Alleles</topic><topic>Chymotrypsin - genetics</topic><topic>Chymotrypsin - metabolism</topic><topic>Defects</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Dipeptidyl-peptidase IV</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Enhancers</topic><topic>Gene expression</topic><topic>Genotype & phenotype</topic><topic>gliptins</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Glucose</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>incretin effect</topic><topic>Incretins - agonists</topic><topic>Insulin resistance</topic><topic>KCNQ1 Potassium Channel - genetics</topic><topic>KCNQ1 Potassium Channel - metabolism</topic><topic>Metabolism</topic><topic>Peptidase</topic><topic>Pharmacogenomic Testing</topic><topic>Pharmacogenomic Variants</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Potassium</topic><topic>Proteins</topic><topic>Studies</topic><topic>Transcription Factor 7-Like 2 Protein - genetics</topic><topic>Transcription Factor 7-Like 2 Protein - metabolism</topic><topic>Type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tká, Ivan</creatorcontrib><creatorcontrib>Gotthardová, Ivana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tká, Ivan</au><au>Gotthardová, Ivana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>17</volume><issue>7</issue><spage>795</spage><epage>804</epage><pages>795-804</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies.
rs7903146 C>T and
rs7202877 T>G minor allele carriers were both associated with a smaller reduction in HbA1c after gliptin treatment when compared with major allele carriers. After replication in further studies, these observations could be of clinical significance in helping to identify patients with potentially lower or higher response to gliptin treatment.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27166975</pmid><doi>10.2217/pgs-2016-0011</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2416 |
| ispartof | Pharmacogenomics, 2016-05, Vol.17 (7), p.795-804 |
| issn | 1462-2416 1744-8042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1793903572 |
| source | MEDLINE; PubMed Central |
| subjects | Alleles Chymotrypsin - genetics Chymotrypsin - metabolism Defects Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Diabetes Mellitus, Type 2 - metabolism Dipeptidyl-peptidase IV Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Enhancers Gene expression Genotype & phenotype gliptins GLP-1 receptor agonists Glucagon-Like Peptide-1 Receptor - agonists Glucose Humans Hypoglycemic Agents - pharmacokinetics Hypoglycemic Agents - therapeutic use incretin effect Incretins - agonists Insulin resistance KCNQ1 Potassium Channel - genetics KCNQ1 Potassium Channel - metabolism Metabolism Peptidase Pharmacogenomic Testing Pharmacogenomic Variants Polymorphism, Single Nucleotide Potassium Proteins Studies Transcription Factor 7-Like 2 Protein - genetics Transcription Factor 7-Like 2 Protein - metabolism Type 2 diabetes mellitus |
| title | Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A06%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenetic%20aspects%20of%20the%20treatment%20of%20Type%202%20diabetes%20with%20the%20incretin%20effect%20enhancers&rft.jtitle=Pharmacogenomics&rft.au=Tk%C3%A1,%20Ivan&rft.date=2016-05-01&rft.volume=17&rft.issue=7&rft.spage=795&rft.epage=804&rft.pages=795-804&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2016-0011&rft_dat=%3Cproquest_cross%3E1793903572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2326932227&rft_id=info:pmid/27166975&rfr_iscdi=true |